# Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)

> **NCT03783078** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 55 (actual)

## Conditions studied

- Merkel Cell Carcinoma

## Interventions

- **DRUG:** Pembrolizumab (MK-3475)

## Key facts

- **NCT ID:** NCT03783078
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-25
- **Primary completion:** 2022-02-15
- **Final completion:** 2024-02-15
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2025-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03783078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03783078, "Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03783078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*